lystn

https://accadandkoka.com/wp-content/uploads/2018/11/photo-e1542397341342.png ()David C. Norris, MD Patients come in all sizes and shapes, and with varying tolerance for complications and risk.  Is it plausible that a single dosing regimen can optimize treatment for everybody?  If not, what is keeping the pharmaceutical industry from endorsing a more dynamic and patient-centered drug dosing regimen? Our guest is Dr. David Norris, a physician, mathematician, and inventor.  David operates a scientific and statistical consultancy focused on methodology development for ‎precision-medicine applications. He developed Dose Titration Algorithm Tuning (DTAT), a methodological framework that conceives dose individualization as a seamless learning process, beginning in early-phase trials and continuing throughout the drug development process.  Before earning his M.D. at Brown University, he worked in diverse application areas including mathematical finance, operations research and systems engineering. GUEST: David C. Norris, MD.  https://www.patreon.com/DTAT (Patreon) and https://twitter.com/davidcnorrismd?lang=en (Twitter) LINKS: Norris DC. Dose Titration Algorithm Tuning (DTAT) should supersede ‘the’ Maximum Tolerated Dose (MTD) in oncology dose-finding trials. F1000Research. 2017 (https://f1000research.com/articles/6-112/v3 (open access)) Norris DC. One-size-fits-all dosing in oncology wastes money, innovation and lives. Drug Discovery Today. 2018 (https://www.sciencedirect.com/science/article/pii/S1359644617303586 (open access)) Norris DC. Precautionary Coherence Unravels Dose Escalation Designs. bioRxiv. 2017 (https://www.biorxiv.org/content/early/2017/12/29/240846 (open access))  WATCH ON YOUTUBE: https://youtu.be/h48jMkJ8LaM (Watch the episode) on our YouTube channel. Support this podcast